XGEVA Denosumab 120 Injection is a human monoclonal antibody which is administered via subcutaneous route for treatment of osteoporosis, treatment-induced bone loss, and cell tumor of bone. It is considered as RANKL inhibitor which is known to work by preventing osteoclast development thus eliminating bone resorption. This chemical inhibits osteoclast maturation and prevents bone from degradation. It comprises denosumab as active compound having molar mass of 144.7 g/mol. XGEVA Denosumab 120 Injection is also used to prevent fractures in bones that might occur due to certain types of cancers. It is also known to play an important role in increasing bone strength and density.